Evaluating of a new role of mesenchymal cells for immunity in pancreatic cancer and new standard for treatment of pancreatic cancer by using the immunity

在胰腺星状细胞（PSCs）中发现了Toll样受体的一些亚型。此外，在对胰腺癌大块组织mRNA的mRNA分析中，当术后不进行辅助治疗时，FAS高剂量组预后较差。此外，我们发现表达CD10抗原的PSCs亚群，显示出淋巴细胞的特化，促进了肿瘤的恶性行为。对PSCs亚型的评估进一步深入，发现CD271表达可能与癌细胞的抵抗因子有关，CD146表达可能控制癌细胞的侵袭。此外，利用磁分离设备从肿瘤中制备分离巨噬细胞，未来有望发展到巨噬细胞和间充质细胞靶向特异性药物治疗的癌细胞和基质的调控机制阐明

In pancreatic stellate cells (PSCs), we revealed that some subtypes of Toll LikeReceptor were found. Moreover, in the mRNA analysis for mRNA derived from a pancreatic cancer bulk organization, it became a bad prognosis in the FAS high quantity group, when the postoperative adjunct therapy was not being performed,. Furthermore, we revealed that PSCs subpopulation which expressed CD10 antigen, which shows specialization of a lymphocyte, has contributed to the malignant behaviors of a tumor. This evaluation for PSCs subtyping further progressed and found out a possibility that CD271 expression was related to a resistance factor to cancer cells, and a possibility that CD146 expression had controlled invasion of cancer cells. Moreover, macrophage preparative isolation from a tumor was performed by using magnetic-separation equipment, and it has expected to progress to the control mechanism elucidation of a cancer cell and stroma targetingspecific new medical treatment by the macrophages and mesenchymal cells in the future